Elevated levels of PAI-1 activity and t-PA antigen are associated with newly diagnosed abnormal glucose regulation in patients with ST-elevation myocardial infarction

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 8, 2011, Pages 1468-1474

  Knudsen, Eva Cecilie ^a   Seljeflot, I ^a   Abdelnoor, M ^b   Eritsland, J ^a   Mangschau, A ^a   Muller C ^a   Arnesen, H ^a   Andersen, G O ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Abnormal glucose regulation; Fibrinolytic disorders; ST elevation myocardial infarction; Thrombosis

Indexed keywords

GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; FEMALE; FOLLOW UP; HEMOSTASIS; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOSIS;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOSTASIS; HUMANS; INPATIENTS; LOGISTIC MODELS; MALE; MYOCARDIAL INFARCTION; NORWAY; ODDS RATIO; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; PROTHROMBIN; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; UP-REGULATION; VON WILLEBRAND FACTOR;

EID: 80051586076     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04377.x     Document Type: Article

References (38)

1. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995; 44: 369-74.
2. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-4.
3. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M, Standl E, Soler-Soler J, Ohrvik J. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880-90.
4. Hu DY, Pan CY, Yu JM. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 2006; 27: 2573-9.
5. Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H, Andersen GO. Abnormal glucose regulation in patients with acute ST- elevation myocardial infarction-a cohort study on 224 patients. Cardiovasc Diabetol 2009; 8: 6.
6. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di AE, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22.
7. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
8. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
9. Ziegler D. Type 2 diabetes as an inflammatory cardiovascular disorder. Curr Mol Med 2005; 5: 309-22.
10. Grant PJ. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin 2005; 21(Suppl. 1): S5-12.
11. Verkleij CJ, Nieuwdorp M, Gerdes VE, Morgelin M, Meijers JC, Marx PF. The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor. Thromb Haemost 2009; 102: 460-8.
12. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989; 9: 362-7.
13. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
14. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.
15. Sauls DL, Banini AE, Boyd LC, Hoffman M. Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. J Thromb Haemost 2007; 5: 638-9.
16. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30years. Thromb Haemost 2006; 95: 49-55.
17. Jessani SS, Lane DA, Shantsila E, Watson T, Millane TA, Lip GY. Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. Ann Med 2009; 41: 608-18.
18. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, van der Wall EE, Bassand JP et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-53.
19. World Health Organization Department of Noncommunicable Disease Surveillance G. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complication Report of a WHO Consultation 1999, 1-59. Accessed 20 October 2005.
20. World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia Report of a WHO/IDF Consultation 2005, 1-46. Accessed 1 March 2007.
21. Chrusciel P, Goch A, Banach M, Mikhailidis DP, Rysz J, Goch JH. Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. Med Sci Monit 2009; 15: RA203-8.
22. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction. Circulation 2000; 101: 101-8.
23. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. Principles and Quantitative Methods. New York, NY: Van Nostrand Reinhold Company Inc; 1982.
24. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.
25. Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycemia: a prothrombotic factor? J Thromb Haemost 2010; 8: 1663-9.
26. Esper RJ, Vilarino JO, Machado RA, Paragano A. Endothelial dysfunction in normal and abnormal glucose metabolism. Adv Cardiol 2008; 45: 17-43.
27. Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Muller C, Arnesen H, Andersen GO. Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study. Cardiovasc Diabetol 2010; 9: 47.
28. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-83.
29. Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res 2001; 103(Suppl. 1): S7-19.
30. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-72.
31. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009; 42: 1331-46.
32. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-60.
33. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, Birkeland K. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995; 44: 611-6.
34. Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, van der Poll PT. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006; 55: 1807-12.
35. Dobrovolsky AB, Titaeva EV. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc) 2002; 67: 99-108.
36. Mansfield MW, Heywood DM, Grant PJ. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 160-4.
37. Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem 1993; 39: 683-6.
38. Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007; 92: 4352-8.